Free Trial

Amedisys, Inc. (NASDAQ:AMED) Short Interest Update

Amedisys logo with Medical background

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Amedisys, Inc. (NASDAQ:AMED - Get Free Report) saw a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 3,200,000 shares, anincreaseof42.9% from the July 15th total of 2,240,000 shares. Based on an average daily volume of 482,600 shares, the short-interest ratio is presently 6.6 days. Currently,10.0% of the company's shares are sold short. Currently,10.0% of the company's shares are sold short. Based on an average daily volume of 482,600 shares, the short-interest ratio is presently 6.6 days.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded shares of Amedisys from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 24th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $100.50.

Read Our Latest Stock Analysis on AMED

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AMED. Allworth Financial LP grew its position in Amedisys by 155.8% in the second quarter. Allworth Financial LP now owns 289 shares of the health services provider's stock valued at $28,000 after acquiring an additional 176 shares during the last quarter. Hexagon Capital Partners LLC boosted its holdings in Amedisys by 108.1% in the first quarter. Hexagon Capital Partners LLC now owns 310 shares of the health services provider's stock valued at $29,000 after acquiring an additional 161 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in Amedisys by 56.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider's stock valued at $31,000 after acquiring an additional 120 shares during the last quarter. Fifth Third Bancorp boosted its holdings in Amedisys by 68.1% in the first quarter. Fifth Third Bancorp now owns 348 shares of the health services provider's stock valued at $32,000 after acquiring an additional 141 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Amedisys in the second quarter valued at approximately $32,000. Institutional investors and hedge funds own 94.36% of the company's stock.

Amedisys Trading Up 0.0%

Shares of NASDAQ:AMED traded up $0.03 during mid-day trading on Friday, reaching $101.01. The stock had a trading volume of 1,060,057 shares, compared to its average volume of 780,222. The company has a current ratio of 1.36, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. The firm has a market cap of $3.32 billion, a PE ratio of 39.30, a price-to-earnings-growth ratio of 1.34 and a beta of 0.89. The firm has a 50 day simple moving average of $98.47 and a two-hundred day simple moving average of $95.04. Amedisys has a twelve month low of $82.15 and a twelve month high of $101.02.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The health services provider reported $1.54 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.15. Amedisys had a net margin of 3.56% and a return on equity of 12.91%. The company had revenue of $621.86 million during the quarter, compared to analysts' expectations of $614.61 million. During the same period last year, the business earned $0.98 EPS. The business's quarterly revenue was up 5.2% on a year-over-year basis. On average, research analysts predict that Amedisys will post 4.4 EPS for the current fiscal year.

Amedisys Company Profile

(Get Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Featured Stories

Should You Invest $1,000 in Amedisys Right Now?

Before you consider Amedisys, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.

While Amedisys currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.